Black Diamond Therapeutics Presents Promising BDTX-1535
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging...
Source: globenewswire.com
📰 Trigger Trial News
Trigger Trial News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Trigger Trial. Real-time updates on events, politics, business and more.
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment ...
Source: marketscreener.com
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with ...
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment
Source: eagletribune.com
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data In Patients With Recurrent Glioblastoma At 2024 American Society Of Clinical Onc...
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging ant
Source: menafn.com
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, Mass., April 24, 2024 -- Black Diamond Therapeutics, Inc. , a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with...
Source: marketscreener.com